Cargando…
Prediction of a clinically effective dose of THY1773, a novel V (1B) receptor antagonist, based on preclinical data
THY1773 is a novel arginine vasopressin 1B (V(1B)) receptor antagonist that is under development as an oral drug for the treatment of major depressive disorder (MDD). Here we report our strategy to predict a clinically effective dose of THY1773 for MDD in the preclinical stage, and discuss the impor...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252455/ https://www.ncbi.nlm.nih.gov/pubmed/33734452 http://dx.doi.org/10.1002/bdd.2273 |